摘要
目的探讨帕罗西汀联合利培酮治疗强迫症的临床疗效及安全性。方法将42例强迫症患者随机分为两组各21例,研究组口服帕罗西汀联合利培酮治疗,对照组单用氯米帕明治疗,观察10 w。于治疗前及治疗10 w末采用强迫症量表、汉密顿焦虑量表、汉密顿抑郁量表评定疗效,副反应量表评定不良反应。结果治疗10 w末,研究组痊愈率为33.33%、显效率为80.95%、总有效率为100%;对照组分别为19.05%、33.33%、95.23%,研究组疗效显著优于对照组(χ2=4.13,P<0.05)。各量表评分治疗10 w末两组均较治疗前有显著下降(P均<0.01),但研究组均较对照组下降显著(P均<0.05)。结论帕罗西汀联合利培酮治疗强迫症疗效显著,优于单用氯米帕明治疗,且安全性高,依从性好。
Objective To explore the clinical efficacy and safety of paroxetine combining with risperldone in the treatment of obsessive-compulsive disorder（OCD）. Methods 42 patients with OCD were randomly divided into research group（n=21） receiving paroxetine plus risperldone and control（n=21） doing single paroxetine for 10 weeks. Clinical efficacies were assessed with the Yale-Brown Obsessive Compulsive Scale （Y-BOCS） ,Hamilton Anxiety Scale（HAMA） and Hamilton Depression Scale（HAMD） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before and after treatment. Results After 10 week treatment, recovery, excellence and total effectiveness rate was 33.33%, 80.95% and 100% in the research and 19.05%, 33.33% and 95.23% in the control, respectively, which showed that the former were better than the latter（P〈0.05）. Scores of all scales lowered more significantly after treatment compared with pre-treatment in both 2 groups（all P〈0.01）, and those did more significantly in the research than in the control（all P〈0.05）. Conclusion Paroxetine plus risperidone has evident effects,higher safety and better compliance in the treatment of obsessive compulsive disorder compared with single clomipramine.
出处
《临床心身疾病杂志》
CAS
2008年第5期398-399,共2页
Journal of Clinical Psychosomatic Diseases
关键词
强迫症
利培酮
帕罗西汀
氯米帕明
Obsessive-compulsive disorder
risperidone
paroxetine
clomipramine
